Edoxaban for Stroke Prevention in Atrial Fibrillation and Age-Adjusted Predictors of Clinical Outcomes in Routine Clinical Care

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985807%3A_____%2F23%3A00560446" target="_blank" >RIV/67985807:_____/23:00560446 - isvavai.cz</a>

Result on the web

<a href="https://dx.doi.org/10.1093/ehjcvp/pvac042" target="_blank" >https://dx.doi.org/10.1093/ehjcvp/pvac042</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/ehjcvp/pvac042" target="_blank" >10.1093/ehjcvp/pvac042</a>

Result language

angličtina

Original language name

Edoxaban for Stroke Prevention in Atrial Fibrillation and Age-Adjusted Predictors of Clinical Outcomes in Routine Clinical Care

Original language description

AIMS: Patients with atrial fibrillation (AF) treated with oral anticoagulation still suffer from cardiovascular complications including cardiovascular death, stroke, and major bleeding. To identify risk factors for predicting stroke and bleeding outcomes in anticoagulated patients, we assessed 2-year outcomes in patients with AF treated with edoxaban in routine care. We also report the age-adjusted risk predictors of clinical outcomes. METHODS AND RESULTS: The Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (ETNA-AF) Europe (NCT02944019) is a prospective, multi-centre, post-authorisation, observational study with an overall 4-year follow-up conducted in 825 centres enrolling edoxaban-treated patients in 10 European countries. Of the 13 133 patients with AF (mean age: 73.6 ± 9.5 years), 5682 (43.3%) were female. At the 2-year follow-up, 9017/13 133 patients were still on edoxaban, 1830 discontinued treatment including 937 who died (annualised event rate of all-cause death was 3.87%). 518 (2.14%) patients died of cardiovascular causes, 234 (0.97%) experienced major bleeding and 168 (0.70%) experienced stroke or systemic embolic events (SEE). Intracranial haemorrhage was noted in 49 patients (0.20%). History of transient ischaemic attack (TIA) at baseline was the strongest predictor of ischaemic stroke or SEE (Wald χ2: 73.63, P < 0.0001). Low kidney function at baseline was the strongest predictor of major bleeding (Wald χ2: 30.68, P < 0.0001). History of heart failure (HF) was the strongest predictor of all-cause (Wald χ2: 146.99, P < 0.0001) and cardiovascular death (Wald χ2: 100.38, P < 0.0001). CONCLUSION: Patients treated with edoxaban in ETNA-AF-Europe reported low 2-year event rates in unselected AF patients. Prior stroke, reduced kidney function, and HF identify patients at high risk of stroke, bleeding and all-cause/cardiovascular death, respectively.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Heart Journal-Cardiovascular Pharmacotherapy

ISSN

2055-6837

e-ISSN

2055-6845

Volume of the periodical

9

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

47-57

UT code for WoS article

000836165300001

EID of the result in the Scopus database

2-s2.0-85144586435